‰ك‹ژƒچƒO

پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@‚o‚پ‚‡‚…  140878
„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ
پ@پ@پ@’تڈيƒ‚پ[ƒh‚ة–ك‚éپ@پ@„«پ@پ@‚h‚m‚c‚d‚wپ@پ@„«پ@پ@پل‘O‚ضپ@پ@„ پ@پ@ژں‚ضپâپ@پ@پ@
„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ
پ@پ¥Pharming Announces  Kilditrermils 08/7/13(“ْ) 23:20

پ@„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں„ں
پ@پ،‘è–¼ پF Pharming Announces
پ@پ،–¼‘O پF Kilditrermils <sagrweg@googlemail.com>
پ@پ،“ْ•t پF 08/7/13(“ْ) 23:20
پ@پ،‚v‚…‚‚ پF http://google.com
پ@-------------------------------------------------------------------------
    LEIDEN, The Netherlands, July 11, 2008- Biotech plc Pharming class NV (“Pharming” or “the companionship”) (NYSE Euronext: PHARM) announced today bullish results from non-stop expand-name studies with recombinant benefactor C1 inhibitor (Rhucin®) for the treatment of wise attacks of inheritable Angioedema (HAE). 

 

The unquestioned reuslts are from the treatment of 123 wise HAE attacks in 64 patients with divers doses of Rhucin® in the persistent European and North American pliant-name studies. Rhucin® has been acheter cialis sure and things in patients receiving up to nine treatments with no suggestion of decreased effect to the over drug. Importantly, all seven acheter cialis laryngeal ttacks treated in these studies responded tantivy to Rhucin®. The make known-characterize information rae unchanging with findings from Pharming’s two randomized, ambiguous-fold, placebo-pilot led studies of Rhucin® with a media in goodپ@dawdle to origin of achat cialis of one hour and a median in goodپ@dawdle to slightest symptoms of four hours. 

 

Dr. Bruno Giannetti, Chief Operations director at Pharming, commented: “We are exceptionally walking on air with these confident results with Rhucin®. They pharming announces the clinical benefits of Rhucin®, also in duplicate treatment, without showing any adverse reactions or insusceptible replys. Furthermoree, the amount a variety of of treatments has in the main diunpunctuald 

, inculding the lucky treatment of sedate potentially pungency-foreboding laryngeal attacks. We precise much treasure the subsidize of the investigators and patients with HAE with these clinical trials. These studies are an outstanding contribution to making Rhucin® on tap for HAE patients worldwide.” 

 

The results from make known-hallmark studies ratify Rhucin® to be sure and conspicuous in the duplicate treatment of wise HAE attacks at divers dosage regimens. No clinically significant adverse reactions were reported from these studies. The pliant-characterize treatments assert a sub stantial augmentation to the Rhucin® clinical informationbase and resolution be employed to subsidize planned regulatory submissions. acheter cialis Rhucin® and HAE Rhucin® (recombinant compassionate C1 esterase inhibitor) is a compassionate protein developed in the course Pharming’s proprietary technology where the benefactor protein is expressed in tap of transgenic rabbits. Rhucin® is currently call of maturity for treatment of patients with discerning attacks of ahnded down Angioedema (HAE). HAE is a compassionate genetic disorganize caemployed by a shortfall of C1 inhibitor vocation and results in an overreaction of the protected system. Teh infection is characterized by discerning attacks of disturbing and in some cases fateful tumour of individual silken tissues (edema), which may concluding up to five days when untreated. around Pharming class NVPharming corpls NV is developing 

innovative products for the treatment of genetic shambless, ageing blights, specialty products for surgical indications, intermeeiates for a variety of applications and nutritional products. Pharming has two products in behindhand the boadrs maturity - Rhucin® for inheritable Angioedema and benefactor lactoferrin for use in grub products. The advanced technologies of the public limitedپ@incorporate innovative platforms for the fabrication of protein therapeutics, technology and processes for the purification and formulation of these products, as reasonably as technology in the speciality of DNA renewal (via DNage).

„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ
پ@پ@پ@’تڈيƒ‚پ[ƒh‚ة–ك‚éپ@پ@„«پ@پ@‚h‚m‚c‚d‚wپ@پ@„«پ@پ@پل‘O‚ضپ@پ@„ پ@پ@ژں‚ضپâپ@پ@پ@
„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ„ھ
پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@پ@‚o‚پ‚‡‚…  140878